Triple–Hormone-Receptor Agonist Retatrutide for Obesity
The landmark 338-person Phase 2 trial reporting up to 24.2% mean weight reduction at 48 weeks. The essential starting paper.
The reading and watch list
15 retatrutide resources
Start with the journal articles. Use official releases for the newest unpublished Phase 3 data. Then use independent reporting and videos to understand the broader story and the gray market.
15 resources
Retatrutide for People With Type 2 Diabetes — Phase 2
Randomized trial of A1C and weight effects across several doses, with placebo and dulaglutide comparator groups.
Retatrutide for Metabolic Dysfunction–Associated Steatotic Liver Disease
A 98-person Phase 2a substudy measuring liver-fat change and the percentage reaching normal liver-fat levels.
Effects of Retatrutide on Body Composition
DXA substudy examining total fat mass and the proportion of lean-mass loss during retatrutide treatment.
TRANSCEND-T2D-1 Phase 3 Trial
Peer-reviewed 40-week Phase 3 monotherapy trial reporting A1C changes up to −1.94 points and weight change up to −15.3%.
TRIUMPH-5: Retatrutide Versus Tirzepatide
The official registry record for the ongoing head-to-head trial designed to test the comparison that cross-trial headlines cannot settle.
No-Prescription Online Semaglutide Purchases
A small test-buy study documenting illegal pharmacy sites, nondelivery, false purity claims, mislabeled quantity and elevated endotoxin. It concerns semaglutide, not retatrutide, so its limits matter.
TRIUMPH-1 Phase 3 Topline Results
The sponsor’s detailed May 2026 release with efficacy and treatment-regimen estimates, adverse-event rates and the 104-week extension.
TRIUMPH-2 and TRIUMPH-3 Topline Results
July 2026 results in obesity with type 2 diabetes and severe obesity with cardiovascular disease, plus Lilly’s stated regulatory-submission plan.
Reuters: 28% Weight Loss in the Pivotal Trial
Independent reporting on TRIUMPH-1, including the efficacy finding, dysesthesia signal, discontinuation rate and expected regulatory path.
UCHealth: A Clinician Explains the New Results
An accessible June 2026 discussion of efficacy, comparisons, side effects, knee pain, nutrition and the limits of the available evidence.
CBS News Investigation: Online Retatrutide Sales
A September 2026 investigation into websites selling an experimental drug and how trust seals and marketing can make unapproved products look legitimate.
ABC News: New Retatrutide Data Explained
ABC News chief medical correspondent Dr. Tara Narula summarizes the May 2026 trial announcement for a general audience.
CBS News: Doctors Promoting Unregulated Retatrutide
Video reporting on clinicians advertising or supplying retatrutide before FDA approval and outside controlled clinical trials.
Yale: Dr. Ania Jastreboff on Obesity Medication
A longer discussion with a lead retatrutide investigator about obesity biology and the medication revolution that provides useful context beyond one drug.
How this list was selected
The collection prioritizes primary human research, the federal trial registry, official development information, independent reporting and videos from established news or academic sources. Company news releases are included because some 2026 Phase 3 data had not yet been fully published; they are labeled as topline, not treated as equivalent to peer-reviewed journal reports.
We excluded dosing tutorials, vendors, affiliate pages, anecdotal transformation videos and content that directs viewers to buy unapproved peptides.
FREE TEN PAGE RETATRUTIDE REPORT
The latest peer-reviewed evidence on efficacy, safety, and where retatrutide clinical trials stand today. No cost, no obligation.